AMD vs OCUL: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
AMD (Advanced Micro Devices) and OCUL (Ocular Therapeutix) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
AMD vs OCUL: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMD | OCUL | What it tells you |
|---|---|---|---|
| Forward P/E | 34.45 | -5.53 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.47 | 0.88 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 75% of range | 19% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.04 | 3.07 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMD and OCUL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMD and OCUL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMD and OCUL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Advanced Micro Devices (AMD) do?
Advanced Micro Devices (AMD) designs CPUs, GPUs, and adaptive computing chips. The company has two main client-facing CPU lines: Ryzen for consumer PCs and EPYC for data center servers. EPYC has gained significant share against Intel Xeon in cloud and enterprise data centers over the past five years. The Instinct GPU line (MI300X, MI325X, MI350, MI400) is AMD's AI accelerator platform and the primary direct competitor to NVIDIA's data center GPUs.
What does Ocular Therapeutix (OCUL) do?
Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Its only approved, revenue-generating product is DEXTENZA, a dexamethasone insert placed in the tear duct to treat inflammation and pain after eye surgery and, more recently, allergic eye itching. DEXTENZA generates modest, roughly flat sales, so the company is effectively pre-profit and funds itself with a large cash balance while it invests heavily in clinical development.
AMD vs OCUL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AMD drivers: Instinct AI GPU ramp; EPYC server share gains.
- OCUL drivers: AXPAXLI in wet AMD; Expanding Phase 3 pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: NVIDIA's structural advantages in AI (CUDA ecosystem, manufacturing capacity allocations from TSMC, customer relationships) make AI GPU share gains harder than the hardware comparison alone suggests. For OCUL, the stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs.
AMD or OCUL: which should you pick?
AMD vs OCUL: the full fundamentals
AMD. AMD trades at a premium P/E reflecting the AI accelerator growth story and EPYC share gains. The valuation depends on continued execution against NVIDIA in AI; multiple compresses quickly if Instinct share gains stall.
OCUL. Ocular is effectively a pre-profit biotech: DEXTENZA sales were roughly flat and small while R&D spending rose to fund several Phase 3 trials, widening the net loss. The market capitalization of around $1.8 billion is many times trailing revenue because investors are pricing the potential of AXPAXLI rather than current earnings, which is typical for a clinical-stage biotech with a de-risked lead asset.
Headline figures (approximate, early 2026): AMD shows revenue (ttm) ~$30 billion, operating margin ~25% (improving as data center mix grows), net income (ttm) ~$4 billion (GAAP; higher non-GAAP), eps (ttm) ~$2.50; OCUL shows revenue (fy2025) ~$52 million, revenue (q1 2026) ~$10.8 million, net loss (q1 2026) ~-$88.6 million, r&d expense (q1 2026) ~$66.2 million.
The bottom line: AMD vs OCUL
AMD and OCUL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMD and OCUL exposure against your real portfolio. It is not an investment adviser.
Wondering how AMD or OCUL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Advanced Micro Devices with AI
Connect the broker you already use and ask Walnut's AI how AMD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AMD and OCUL?
+
Advanced Micro Devices (AMD) designs CPUs, GPUs, and adaptive computing chips. Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMD or OCUL the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMD or OCUL?
+
On forward P/E (as of August 2026), AMD trades at 34.45x and OCUL at -5.53x, so OCUL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMD and OCUL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMD vs OCUL?
+
AMD: NVIDIA's structural advantages in AI (CUDA ecosystem, manufacturing capacity allocations from TSMC, customer relationships) make AI GPU share gains harder than the hardware comparison alone suggests. Intel's eventual recovery in server CPUs is a multi-year risk. OCUL: The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting a net loss of about $88.6 million in the first quarter of 2026 as R&D climbed, and it may need additional capital that could dilute shareholders. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue is too small to cushion a pipeline disappointment.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMD or OCUL; figures are approximate and dated (as of August 2026). Verify current data before investing.